Navigation Links
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc.
Date:1/6/2009

BALTIMORE, Jan. 6 /PRNewswire/ -- FASgen, Inc. is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research and Development division affiliates the opportunity to discover and develop novel small molecule inhibitors of the fatty acid biosynthesis pathway via selective inhibition of Fatty Acid Synthase (FAS) for use in Oncology. The FASgen researchers have extensive experience studying the over-expression of FAS, an enzyme over-expressed in virtually all solid tumors. The inhibition of FAS causes tumor cell apoptosis and holds promise for new therapeutic treatments for cancer.

The economic terms of the research collaboration were not disclosed.

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University. The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer. Additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders including diabetes, dysplipidemia fatty liver disease and non-alcoholic steatohepatitis. A final group of compounds have the potential of specific therapeutics against TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at www.fasgen.com.


'/>"/>
SOURCE FASgen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. B2B Marketing Pro Toby Younis Announces Free Webcast on "BuzzMaking"
2. Alfacell Announces Receipt of NASDAQ Panel Decision
3. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
4. Go Ask Alice ... Nationally Recognized Life Coach & Psychotherapist, Alice Donavin, LCSW Announces the Implementation of Office/House Calls to her Newly Launched Philadelphia Practice
5. Mobile Massage Team Announces Eleven New Therapist Members in the Northeast U.S. Region
6. Misonix Announces New HIFU Distribution Agreement for Italy
7. Four Rivers Software Systems Announces Integration with ePartsFinder from PartsSource
8. Summa Health Network Announces Contract with MDdatacor to Support Multi-Insurer Health Care Quality Initiative; Initiative to Use Clinical Data to Supplement Claims Data and Enhance Outcomes
9. Dialysis Corporation of America Announces Acquisition of Maryland Dialysis Center
10. SXC Health Solutions announces contract with PharMerica
11. MedCath Corporation Announces Completion of Sale of Equity Interest in Joint Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... April 22, 2017 , ... ... as Vice President of Sales and Business Development at OAKWORKS, Inc. Mr. ... engagements, business development, and strategic planning for the company. Recognized industry-wide as ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... An April ... of a pair of ancient teeth, which reveal a great deal about prehistoric ice-age ... a sharp stone may have been used to remove decayed dental matter, and that ...
(Date:4/21/2017)... ... April 21, 2017 , ... The staff at Palm Beach Face is proud to ... in the 2017 London Marathon. Set to take place on April 23rd, the London Marathon ... Dr. Schwartz will run as part of team EMPOWER, raising money for the international charity, ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Chicago plastic surgeon, ... removal of osteoma. An osteoma is a benign bony lump located on the forehead ... and can cause difficulties with sight and pain. Dr. Shah has discovered an approach ...
(Date:4/21/2017)... Wis. (PRWEB) , ... April 21, 2017 , ... ... today announced that its B-595 and B-7569 vinyl label materials ... identification and warning labels are tested to remain intact and legible, for use on ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology: